Sanofi Invest Advisor

Dupixent® (dupilumab) Gains Approval in China as Groundbreaking Biologic for COPD Patients Sep 28, 2024

Phase 3 Trial of Dupixent® Shows Significant Efficacy in Treating Chronic Spontaneous Urticaria Sep 11, 2024

Kymera (KYMR) and Sanofi (SNY) Broaden Research Studies on Key Treatment KT-474 Jul 10, 2024

Sanofi Contemplates a $20B Spinoff of Its Consumer Health Division Amidst Interest from Major Buyout Firms Nov 16, 2023